Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.58 |
| ▸ | CES1 | P23141 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30081009 | 0.87 | CES2 (0.58) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL7685019 | 0.85 | CES2 (0.61) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL5224837 | 0.85 | CES2 (0.56) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL10308375 | 0.84 | PDK2 (0.46) | ALDH1A1ALOX15GAATP53MEN1 | |
| SCHEMBL1155548 | 0.83 | CES2 (0.55) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL12780284 | 0.83 | CES2 (0.61) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL11769973 | 0.83 | ALDH1A1 (0.55) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL4596958 | 0.82 | ALB (0.60) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL9017503 | 0.82 | CES2 (0.53) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL19333968 | 0.80 | CES2 (0.51) | CES2CES1ALDH1A1ALOX15GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | C4 THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-26 | — | — | US | disclosed |
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10716788-B2 | Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2020-07-21 | — | — | US | disclosed |
| US-20200048228-A1 | ALVOCIDIB PRODRUGS AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| EP-1507757-A1 | LACTAMS USED AS ANTI-VIRAL AGENTS | Bayer HealthCare AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| EP-1499603-A1 | ANTIVIRAL LACTONE-UREAS | Bayer Aktiengesellschaft (DE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003097595-A1 | LACTAMS USED AS ANTI-VIRAL AGENTS | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003089421-A1 | ANTIVIRAL LACTONE-UREAS | BAYER HEALTHCARE AG (DE) | 2003-10-30 | — | — | WO | disclosed |
| EP-0273647-B1 | COUMARAN DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1992-03-11 | — | — | EP | disclosed |
| US-4857516-A | Coumaran derivatives and their pharmaceutical use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0273647-A1 | Coumaran derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10716788-B2 | Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, LCK, SYK | CES2 3380/4885CES1 3123/4885ALDH1A1 4467/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | CES2 417/4885CES1 79/4885ALDH1A1 132/4885 |
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ADSL, SLC35B2, ADORA1 | CES2 2295/4885CES1 1956/4885ALDH1A1 136/4885 |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | CRBN, IKZF1, IKZF3 | CES2 2962/4885CES1 2610/4885ALDH1A1 3827/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CES2 4820/4885CES1 3698/4885ALDH1A1 1079/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | CES2 79/4885CES1 70/4885ALDH1A1 1144/4885 |
| US-20070082908-A1 | Bicycle pyrazole derivative | DPP4, DPP7, DPP3 | CES2 436/4885CES1 79/4885ALDH1A1 86/4885 |
| US-20200048228-A1 | ALVOCIDIB PRODRUGS AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CDK2, CDK3 | CES2 4214/4885CES1 2437/4885ALDH1A1 3857/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | CES2 417/4885CES1 79/4885ALDH1A1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.